Report cover image

Multiple Sclerosis Therapeutics Market

Published Jul 14, 2025
Length 148 Pages
SKU # CMI20302771

Description

Multiple sclerosis (MS) is a chronic autoimmune disorder that affects the central nervous system (CNS). It is caused when the immune system attacks myelin, the protective sheath surrounding nerve fibers of the CNS. The damage disrupts communication between the brain and other parts of the body. Symptoms can be mild or severe, depending on the number and location of lesions in the CNS. Common symptoms include fatigue, weakness or numbness in the limbs, poor coordination and balance, vision problems, and cognitive dysfunction. There has been no known cure for MS but medications such as interferons, glatiramer acetate, monoclonal antibodies, corticosteroids can manage the disease symptoms and slow down its progression.

Market Dynamics

Global multiple sclerosis therapeutics market growth is driven by factors like increasing prevalence of multiple sclerosis across both developed and developing nations, growing geriatric population, robust pipeline of new and innovative treatment therapies for multiple sclerosis, surging healthcare spending, and availability of reimbursement schemes. However, high costs associated with multiple sclerosis drugs can hamper the market growth. Emergence of personalized medicines for multiple sclerosis treatment, growing adoption of combination therapies, infusion therapies, and oral drugs for multiple sclerosis treatment can offer market growth opportunities.

Key features of the study
  • This report provides in depth analysis of the global multiple sclerosis therapeutics market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global multiple sclerosis therapeutics market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Biogen, Novartis, Merck, Sanofi, Teva Pharmaceuticals, Bayer, ACORDA THERAPEUTICS and CELGENE.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up gradation, market expansion, and marketing tactics.
  • Global multiple sclerosis therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global multiple sclerosis therapeutics market.
Market Segmentation
  • By Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
  • Beta Interferon
  • Corticosteroids
  • Monoclonal Antibodies
  • Antineoplastic Agent
  • Others
  • By Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
  • Oral
  • Injection
  • Others
  • By Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
  • Key Players Insights
  • Biogen Inc.
  • Novartis AG
  • Merck KGaA
  • Sanofi S. A.
  • Acorda Therapeutics, Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • Bristol-Myers Squibb Company
  • Bayer AG
  • Hoffmann-La Roche AG
  • Viatris Inc. (Mylan NV)
  • Johnson & Johnson
  • EMD Serono, Inc.
  • TG Therapeutics, Inc.
  • Genentech, Inc.
  • Celgene Corporation
  • AbbVie Inc.
  • Amgen Inc.
  • UCB S.A.
  • Sandoz (a Novartis division)
  • Ipsen S.A.

Table of Contents

148 Pages
1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Global Multiple Sclerosis Therapeutics Market, By Drug Class
Global Multiple Sclerosis Therapeutics Market, By Route of Administration
Global Multiple Sclerosis Therapeutics Market, By Distribution Channel
Global Multiple Sclerosis Therapeutics Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER’s Analysis
Merger and Acquisition Scenario
Industry Trends
4. Global Multiple Sclerosis Therapeutics Market, By Drug Class, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Beta Interferon
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Corticosteroids
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Monoclonal Antibodies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Antineoplastic Agent
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Multiple Sclerosis Therapeutics Market, By Route of Administration, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021- 2032
Segment Trends
Oral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Injection
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Multiple Sclerosis Therapeutics Market, By Region, 2020 - 2032, (USD Bn)
Introduction
Market Share (%) Analysis, 2025, 2028 & 2032, (USD Bn)
Market Y-o-Y Growth Analysis (%), 2021 - 2032, (USD Bn)
Regional Trends
North America
Introduction
Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
U.S.
Canada
Latin America
Introduction
Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
Brazil
Argentina
Mexico
Rest of Latin America
Europe
Introduction
Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
Introduction
Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
Introduction
Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
GCC Countries
Israel
Rest of Middle East
Africa
Introduction
Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
Market Size and Forecast, By Country/Region, 2020 - 2032, (USD Bn)
South Africa
North Africa
Central Africa
8. Competitive Landscape
Biogen Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Novartis AG
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Merck KGaA
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Sanofi S. A.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Acorda Therapeutics, Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Teva Pharmaceuticals Industries Ltd.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Bristol-Myers Squibb Company
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Bayer AG
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Hoffmann-La Roche AG
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Viatris Inc. (Mylan NV)
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Johnson & Johnson
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
EMD Serono, Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
TG Therapeutics, Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Genentech, Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Celgene Corporation
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
AbbVie Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Amgen Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
UCB S.A.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Sandoz (a Novartis division)
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Ipsen S.A.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
9. Analyst Recommendations
Wheel of Fortune
Analyst View
Coherent Opportunity Map
10. References and Research Methodology
References
Research Methodology
About us
*Browse 32 market data tables and 28 figures on 'Multiple Sclerosis Therapeutics Market' - Global forecast to 2032
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.